Track Gennex Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 3.48 %
Low
11.3
High
13.0
1 Month returns: 33.85 %
Low
8.3
High
13.0
1 Year returns: 2.01 %
Low
7.1
High
17.3
3 Year CAGR: 13.79 %
Low
7.1
High
29.0
5 Year CAGR: 10.24 %
Low
4.8
High
29.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Gennex Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Gennex Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Gennex Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Gennex Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Gennex Laboratories Ltd.?
The current share price of Gennex Laboratories Ltd. is ₹ 12.18 as of 26 Aug 2026.
What is the market capitalisation of Gennex Laboratories Ltd.?
The market capitalisation of Gennex Laboratories Ltd. stands at ₹ 277.03 Cr.
What is the PE ratio of Gennex Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Gennex Laboratories Ltd. is 14.84 as of the latest trailing twelve months data.
What is the ROE and ROCE of Gennex Laboratories Ltd.?
Gennex Laboratories Ltd. has a Return on Equity (ROE) of 9.02% and a Return on Capital Employed (ROCE) of 7.87% as per the latest financial reports.
What is the 52-week high and low of Gennex Laboratories Ltd.?
The 52-week high of Gennex Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Gennex Laboratories Ltd.?
The dividend yield of Gennex Laboratories Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Gennex Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 62.07% of Gennex Laboratories Ltd. shares.
What sector does Gennex Laboratories Ltd. belong to?
Gennex Laboratories Ltd. operates in the Healthcare sector.
What is the beta of Gennex Laboratories Ltd.?
The beta of Gennex Laboratories Ltd. is 1.34, indicating its price volatility relative to the broader market. Over the past 1 year, Gennex Laboratories Ltd. has delivered an absolute return of -1.62%.
What is the RSI of Gennex Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Gennex Laboratories Ltd. is 70.42, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Gennex Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Stock is cheap and PE TTM is at a discount to industry median
PE TTM of 14.84 indicates that the stock is cheap on a standalone basis. Discount to industry median P/E is decent at -51.42%
What is P/E Ratio?
Median: 30.55
Value 14.84
-0.99726.77
Strong revenue growth and above median growth of industry
The company delivered strong revenue growth of 24.1% for 12-month ended 30 Jun 2026 and the growth was 13.51 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value 24.1
-99.6111701.8
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.16 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year
What is Debt to Equity?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Low but stable ROE
The company reported low ROE of 9.02% for 12-month ended 30 Jun 2026 and ROE declined marginally by -112 bps from 1 year ago
What is ROE (FY)?
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -2.23% for 12-month ended 30 Jun 2026 and the growth was 9.43 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Company's earnings are of low quality
Earnings quality score of 5.1 indicates that the company's earnings are of low quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
5.1 / 100
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Moderate and stable operating margin
The company reported moderate operating margin of 10.33% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 7 bps from 1 year ago
What is Operating profit margin?
Stock in ASM list
The stock has been places in Additional Surveillance Measure (ASM) list (STASM - I).
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
23.38
23.38
23.38
23.38
23.60
23.60
18.42
18.42
18.42
18.42
18.42
19.83
23.62
23.62
23.63
23.63
Indian Promoter
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
22.05
23.38
23.38
23.38
23.38
23.60
23.60
18.42
18.42
18.42
18.42
18.42
19.83
23.62
23.62
23.63
23.63
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
0.00
-
-
-
-
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-
-
-
-
Mutual Funds / UTI
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FI/Bank/Insurance
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Institutions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non-Institution
77.95
77.95
77.95
77.95
77.95
77.95
77.95
77.95
77.95
77.95
76.62
76.62
76.62
76.62
76.39
76.39
81.58
81.58
81.58
81.58
81.58
80.17
76.38
76.38
76.37
76.37
Bodies Corporate
16.81
17.89
18.06
18.15
12.81
5.90
1.90
2.82
1.50
2.20
11.49
11.81
12.42
14.95
16.78
13.33
15.48
14.42
15.56
13.97
12.67
11.42
10.52
13.97
15.07
14.30
Others (incl. Retail)
No. of shareholders
61.14
12,985
60.06
17,981
59.89
18,046
59.80
18,685
65.14
20,685
72.05
35,934
76.05
46,258
75.13
49,846
76.45
56,557
75.75
57,752
65.13
59,036
64.81
58,131
64.20
55,507
61.67
52,892
59.61
50,890
63.06
69,569
66.10
83,818
67.16
87,631
66.02
89,958
67.61
92,212
68.91
92,051
68.75
90,923
65.86
90,057
62.41
86,051
61.30
83,890
62.07
82,644
12.180.0 (0.25%)
2.01% in past 1 year
Corporate Actions
History of Gennex Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Rights Issue(1 new shares @ ₹6 for 2 existing shares)
Ex-date: 21st Jul 2022Announced on: 16th Jul 2022
Stock Split1 : 10
Ex-date: 14th Dec 2009Announced on: 10th Sep 2009
EGM 31 October 2009. Nominal value change from Rs 10 to Rs 1.
Company Profile
Overview of Gennex Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal m...